Tune in at 8am tomorrow for Tome’s first public unveiling of our progress to date in translating programmable gene integration for patients. Lots of exciting progress!

And it’s not just HEK293 data ;) …

#ASGCT2024

Tome’s CSO, John Finn, PhD, will present at TIDES - Informa Connect on 5/17.

He’ll discuss our progress with Integrase-Mediated Programmable Genomic Integration (I-PGI) across integrative gene and cell tx applications.

bit.ly/3xYZ5K2

The Tome team is headed to @asgctherapy’s #ASGCT2024 in Baltimore, May 7-11! We’re looking forward to a week of learning the latest cell and gene insights and supporting our fellow colleagues’ presentations on May 9-10.

Learn more about the abstracts:
bit.ly/3y7ocdn

Pfizer’s first gene therapy, a $3.5 million one-time treatment for hemophilia B, enters a market that has vexed other drugmakers bloomberg.com/news/articles/… $pfe

Dear fellow Americans. Please read this.

From Noah Smith 🐇🇺🇸🇺🇦.

“Americans are still not worried enough about the risk of world war”

noahpinion.blog/p/americans-ar…

The real move is the MD/PhD/JD/MBA. You’re only 40 when you’re done!

Excited to invite all students to the @harvardopenbio Future of Biology Conference 2024!

We are lucky to have an incredible speaker line-up, incl.:
🧬 - george church (@harvardmed)
🌱 - Reshma Shetty (@Ginkgo)
🦾 - Ritu Raman (@MIT)
🧫 - Jonathan Gootenberg + Omar Abudayyeh (@mcgovernmit)

Stoked about the speaker lineup at this year’s Harvard OpenBio Laboratory conference!

It’s huge to see leading professors like george church Omar Abudayyeh Jonathan Gootenberg in the same place as Gingko co-founder Reshma Shetty and many other seeing speakers.

Register here: docs.google.com/forms/d/e/1FAI…

Announcing
THE STATE OF CRISPR and GENE EDITING
A free virtual summit hosted by Kevin Davies Genetic Engineering & Biotechnology News on June 5.
Confirmed speakers include:
David R. Liu
Laura Sepp-Lorenzino
Sam Sternberg
Joe Bondy-Denomy
Prof Alison Van Eenennaam (@BioBeef)
Patrick Hsu
Omar Abudayyeh
Jonathan Gootenberg
webinars.liebertpub.com/e/the-state-of…

Thrilled to share that I’ve joined the Lux Capital team! Looking forward to continue backing and building transformational life sciences companies

Curious about #CRISPR technology?

CRISPR-based systems are moving lightning-fast, but this review from Nature Reviews Molecular Cell Biology can bring you up to speed.

Explore technological advancements, strengths and weaknesses, and the potential impact on human health.

go.nature.com/430sheV

Bullish on american companies and innovation 💪🏼💪🏼

Another interesting conversation with Tome Biosciences’s CEO & president - Rahul Kakkar about Tome recent exiting stealth mode with $250M in funding, its new platform of CRISPR Gene Editing - programmable genomic integration (PGI) & more. #SundayPodcast $XBI 
podcasts.apple.com/il/podcast/bey…

Thrilled to have found a great home for many of the CRISPR based diagnostic and therapeutic technologies we built over the past few years at Proof!

Buckle up — we’ve got a lot of exciting news to share today!

Introducing Ginkgo’s Technology Network: a groundbreaking ecosystem of cutting edge technology partners, all committed to collaborating with Ginkgo to provide new, integrated capabilities to drive success in customer…

Tome’s CEO, Rahul Kakkar, sat down with Theral Timpson of mendelspod to discuss how genomic-based therapies are crucial in curing diseases versus treating them.

bit.ly/42HeUjC

#CRISPR #genomeediting #TomeBio #genomicmedicine

Wonder what that secretive longevity company funded w/ $3B from Jeff Bezos and Yuri Milner has been working on?
SCOOP: Altos Labs latest public program is an oligonucleotide inhibiting the retrotransposon LINE-1 to treat progeria.

/RNA writing

Here's a great breakdown of the new tech by Omar Abudayyeh:

two transformative techs in RNA Biology!

Arguably, for an RNA biologist, this is nearly as important as the first reports on CRISPR/ Cas9.

In the past few weeks, there's been an explosion of new tools for programming DNA and RNA 🧬

A thread with everything you need to know about these new results: